NASDAQ:EXAS - EXACT Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$92.21 +0.40 (+0.44 %)
(As of 04/19/2019 04:00 PM ET)
Previous Close$91.81
Today's Range$87.82 - $93.11
52-Week Range$44.85 - $99.52
Volume3.32 million shs
Average Volume1.83 million shs
Market Capitalization$11.60 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.83
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was founded in 1995 and is headquartered in Madison, Wisconsin.

Receive EXAS News and Ratings via Email

Sign-up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:EXAS
CUSIP30063P10
Phone608-284-5700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$454.46 million
Book Value$5.54 per share

Profitability

Net Income$-175,150,000.00

Miscellaneous

Employees1,977
Market Cap$11.60 billion
Next Earnings Date4/30/2019 (Confirmed)
OptionableOptionable

EXACT Sciences (NASDAQ:EXAS) Frequently Asked Questions

What is EXACT Sciences' stock symbol?

EXACT Sciences trades on the NASDAQ under the ticker symbol "EXAS."

How were EXACT Sciences' earnings last quarter?

EXACT Sciences Co. (NASDAQ:EXAS) posted its earnings results on Thursday, February, 21st. The medical research company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($0.49) by $0.05. The medical research company earned $142.98 million during the quarter, compared to analyst estimates of $143 million. EXACT Sciences had a negative net margin of 38.54% and a negative return on equity of 23.58%. The business's quarterly revenue was up 63.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.18) EPS. View EXACT Sciences' Earnings History.

When is EXACT Sciences' next earnings date?

EXACT Sciences is scheduled to release their next quarterly earnings announcement on Tuesday, April 30th 2019. View Earnings Estimates for EXACT Sciences.

What guidance has EXACT Sciences issued on next quarter's earnings?

EXACT Sciences updated its FY 2019 earnings guidance on Thursday, February, 21st. The company provided EPS guidance of for the period. The company issued revenue guidance of $710-730 million, compared to the consensus revenue estimate of $704.35 million.

What price target have analysts set for EXAS?

12 brokerages have issued 12 month price objectives for EXACT Sciences' stock. Their forecasts range from $84.00 to $120.00. On average, they anticipate EXACT Sciences' share price to reach $100.30 in the next year. This suggests a possible upside of 8.8% from the stock's current price. View Analyst Price Targets for EXACT Sciences.

What is the consensus analysts' recommendation for EXACT Sciences?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for EXACT Sciences in the last year. There are currently 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for EXACT Sciences.

Has EXACT Sciences been receiving favorable news coverage?

Headlines about EXAS stock have trended positive on Friday, according to InfoTrie Sentiment. The research firm rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. EXACT Sciences earned a news impact score of 3.0 on InfoTrie's scale. They also assigned news headlines about the medical research company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days.

Who are some of EXACT Sciences' key competitors?

What other stocks do shareholders of EXACT Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other EXACT Sciences investors own include Novavax (NVAX), Aduro BioTech (ADRO), NVIDIA (NVDA), Micron Technology (MU), Puma Biotechnology (PBYI), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alibaba Group (BABA), Medivation (MDVN) and Celgene (CELG).

Who are EXACT Sciences' key executives?

EXACT Sciences' management team includes the folowing people:
  • Mr. Kevin T. Conroy, Chairman, Pres & CEO (Age 53)
  • Mr. Jeffrey T. Elliott CFA, Chief Financial Officer (Age 41)
  • Mr. Graham P. Lidgard, Chief Science Officer (Age 70)
  • Mr. D. Scott Coward, Chief Admin. Officer, Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Ms. Ana Hooker, Sr. VP of Operations

Who are EXACT Sciences' major shareholders?

EXACT Sciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include KAMES CAPITAL plc (0.42%), Hodges Capital Management Inc. (0.14%), Rhenman & Partners Asset Management AB (0.08%), Strs Ohio (0.05%), EFG Asset Management Americas Corp. (0.02%) and State of Alaska Department of Revenue (0.01%). Company insiders that own EXACT Sciences stock include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Maneesh Arora, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Institutional Ownership Trends for EXACT Sciences.

Which major investors are selling EXACT Sciences stock?

EXAS stock was sold by a variety of institutional investors in the last quarter, including KAMES CAPITAL plc, Hodges Capital Management Inc., State of Alaska Department of Revenue and Oakbrook Investments LLC. Company insiders that have sold EXACT Sciences company stock in the last year include D Scott Coward, Graham Peter Lidgard, Jeffrey Thomas Elliott, Katherine S Zanotti, Kevin T Conroy, Mark Stenhouse, Michael S Wyzga, Scott C Johnson and Thomas D Carey. View Insider Buying and Selling for EXACT Sciences.

Which major investors are buying EXACT Sciences stock?

EXAS stock was purchased by a variety of institutional investors in the last quarter, including Rhenman & Partners Asset Management AB, Strs Ohio, EFG Asset Management Americas Corp., Bfsg LLC, Meeder Asset Management Inc., Nisa Investment Advisors LLC, Fulton Bank N.A. and WoodTrust Financial Corp. View Insider Buying and Selling for EXACT Sciences.

How do I buy shares of EXACT Sciences?

Shares of EXAS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is EXACT Sciences' stock price today?

One share of EXAS stock can currently be purchased for approximately $92.21.

How big of a company is EXACT Sciences?

EXACT Sciences has a market capitalization of $11.60 billion and generates $454.46 million in revenue each year. The medical research company earns $-175,150,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. EXACT Sciences employs 1,977 workers across the globe.

What is EXACT Sciences' official website?

The official website for EXACT Sciences is http://www.exactsciences.com.

How can I contact EXACT Sciences?

EXACT Sciences' mailing address is 441 CHARMANY DRIVE, MADISON WI, 53719. The medical research company can be reached via phone at 608-284-5700.


MarketBeat Community Rating for EXACT Sciences (NASDAQ EXAS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  743 (Vote Outperform)
Underperform Votes:  441 (Vote Underperform)
Total Votes:  1,184
MarketBeat's community ratings are surveys of what our community members think about EXACT Sciences and other stocks. Vote "Outperform" if you believe EXAS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EXAS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel